Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors

Mathilde Brasseur, Alexandra Heurgué-Berlot, Coralie Barbe, Cloé Brami, Jean-Baptiste Rey, Juliette Vella-Boucaud, Fadia Dabouz, Gaëtan Deslée, Florent Grange, Julien Volet, Olivier Bouché, Mathilde Brasseur, Alexandra Heurgué-Berlot, Coralie Barbe, Cloé Brami, Jean-Baptiste Rey, Juliette Vella-Boucaud, Fadia Dabouz, Gaëtan Deslée, Florent Grange, Julien Volet, Olivier Bouché

Abstract

Background: Reactivation of hepatitis B or C virus can occur in patients undergoing chemotherapy. Recommendations for selective or systematic hepatitis B virus testing prior chemotherapy for solid tumors differ. The primary aim was to determine the seroprevalence of hepatitis B or C in a low endemic country. The second objective was to assess the relevance of a questionnaire on hepatitis B/C risk factors to consider a selective screening.

Methods: Patients were prospectively tested for hepatitis B/C markers. HBs antigen positive patients and isolated anti-HBc positive patients with detectable viral load received antiviral preventive treatment. Patients or physicians completed the questionnaire on infection risk factors.

Results: Among the 450 patients included, 388 were tested for all serological markers and had gastrointestinal (63.7%), lung (31.2%) and skin (4.6%) cancers. The prevalence of subjects exposed to hepatitis B virus was 8.5% (33/388). One patient tested positive for HBs antigen and received preventive treatment. Prevalence of subjects exposed to hepatitis C was 1.3% (5/388). The questionnaire sensitivity was 45.5%, 100% and 50% for detecting carriers of hepatitis B, C and one or the other, respectively.

Conclusions: Seroprevalence of hepatitis B was low. Selective screening with the questionnaire was insufficiently sensitive. Systematic screening with serological tests prior to chemotherapy in patients with solid tumors is therefore relevant.

Figures

Fig. 1
Fig. 1
Patients’ management according to their serological status
Fig. 2
Fig. 2
Primary and secondary endpoint populations

References

    1. Institut de Veille Sanitaire (InVS). Prévalence des hépatites B et C en France en 2004. (2007, accessed 17 September 2014)
    1. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182–188. doi: 10.1016/0016-5085(91)90599-G.
    1. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 2000;62(3):299–307. doi: 10.1002/1096-9071(200011)62:3<299::AID-JMV1>;2-0.
    1. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet. 1996;347(8994):92–93. doi: 10.1016/S0140-6736(96)90212-3.
    1. Zuckerman E, Zuckerman T, Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer. 1998;83(6):1224–1230. doi: 10.1002/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>;2-6.
    1. Yeo W, Chan PKS, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J. Med. Virol. 2003;70(4):553–561. doi: 10.1002/jmv.10430.
    1. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br. J. Cancer. 2004;90(7):1306–1311. doi: 10.1038/sj.bjc.6601699.
    1. Ling WHY, Soe PP, Pang ASL, et al. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br. J. Cancer. 2013;108(10):1931–1935. doi: 10.1038/bjc.2013.225.
    1. Liver EAFTSOT. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012;57(1):167–185. doi: 10.1016/j.jhep.2012.02.010.
    1. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatol. Baltim. Md. 2009;50(3):661–662. doi: 10.1002/hep.23190.
    1. Liaw Y-F, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012;6(3):531–561. doi: 10.1007/s12072-012-9365-4.
    1. Weinbaum CM, Williams I, Mast EE et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. Morb. Mortal. Wkly. Rep. Recomm. Rep. Cent. Dis. Control 2008; 57(RR-8):1–20.
    1. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Intern. Med. 2009;150(2):104–110. doi: 10.7326/0003-4819-150-2-200901200-00100.
    1. Hwang JP, Fisch MJ, Lok AS-F, et al. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer. 2013;13:534. doi: 10.1186/1471-2407-13-534.
    1. Lee RSM, Bell CM, Singh JM, et al. Hepatitis B screening before chemotherapy: a survey of practitioners’ knowledge, beliefs, and screening practices. J. Oncol. Pract. Am. Soc. Clin. Oncol. 2012;8(6):325–328. doi: 10.1200/JOP.2012.000597.
    1. Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010;28(19):3199–3202. doi: 10.1200/JCO.2010.30.0673.
    1. Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J. Natl. Compr. Cancer Netw. JNCCN. 2012;10(11):1412–1445.
    1. Dreyling M, Ghielmini M, Marcus R, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO. 2011;22(Suppl 6):vi59–63.
    1. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br. J. Cancer. 1999;81(1):69–74. doi: 10.1038/sj.bjc.6690652.
    1. Kose S, Olmezoglu A, Gozaydin A, et al. Seroprevalence of hepatitis B and C among oncology patients in Turkey. J. Health Popul. Nutr. 2011;29(6):652–655.
    1. Oguz A, Aykas F, Unal D, et al. Hepatitis B and C seroprevalence in solid tumors - necessity for screening during chemotherapy. Asian Pac. J. Cancer Prev. APJCP. 2014;15(3):1411–1414. doi: 10.7314/APJCP.2014.15.3.1411.
    1. Institut de Veille Sanitaire (InVS). Prevalence, morbidity and mortality associated with chronic hepatitis B and C in the French hospitalized population (2004–2011). (2013, accessed 17 September 2014)
    1. Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011;29(24):3270–3277. doi: 10.1200/JCO.2011.35.1635.
    1. Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO. 2004;15(11):1661–1666. doi: 10.1093/annonc/mdh430.
    1. Chang M-H. Hepatitis B virus infection. Semin. Fetal. Neonatal Med. 2007;12(3):160–167. doi: 10.1016/j.siny.2007.01.013.
    1. Institut de Veille Sanitaire (InVS). BEH 22/98 Stratégie de dépistage de l’hépatite C en population générale dans les centres d’examens de santé. Dispositif de veille sanitaire pour la coupe du monde de football, en 1998. (1998, accessed 17 September 2014)
    1. Sypsa V, Hadjipaschali E, Hatzakis A. Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees. Eur. J. Epidemiol. 2001;17(8):721–728. doi: 10.1023/A:1015671627577.
    1. McQuillan GM, Townsend TR, Johannes CB, et al. Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population. Am. J. Epidemiol. 1987;126(3):484–491.
    1. Centers for Disease Control and Prevention DVH - Viral Hepatitis - Hepatitis Risk Assessment. (accessed 17 September 2014)
    1. Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy. (accessed 17 September 2014)

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren